Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Carol Suh
AddedMar 31, 2024
UpdatedMay 31, 2026
Carol Suh

Carol Suh

Board Member, HI-Bio

CrunchbaseLinkedIn

Carol Suh's Career

HI-Bio
HI-Bio

San Francisco, CA, US

Board Member· Board
Orbital Therapeutics
Orbital Therapeutics

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Carol Suh's Career

HI-Bio
HI-Bio
Series B$215M482021San Francisco, CA, US
Board Member· Board

Leadership at HI-Bio

Travis MurdochTravis MurdochCEO

Similar to HI-Bio

ImmuneIDImmuneIDBoston, MA, USImmunology Therapeuticsest. 2020ImmuneIDBoston, MA, US · est. 2020

ImmuneID: A precision immunology firm targeting antibody interactions to combat immune diseases.

Series A · $67M48
ImidomicsImidomicsSan Francisco, CA, USBiotechnology, Drug Discovery, Therapeuticsest. 2015ImidomicsSan Francisco, CA, US · est. 2015

IMIDomics, Inc.: A biotech firm innovating new treatments for immune-inflammatory diseases.

Public · $16.5M23
AibiosAibiosIrvine, CA, USBiotech, Pharmaceuticalsest. 2018AibiosIrvine, CA, US · est. 2018

AIBIOS: Biotech innovator developing novel molecules to treat immune-related diseases.

Public · $850M6
Santa Ana BioSanta Ana BioAlameda, CA, USBiologics, Therapiesest. 2021Santa Ana BioAlameda, CA, US · est. 2021

Santa Ana Bio designs precision biologics using deep cell profiling tech, specializing in autoimmune diseases.

Series A · $35.3M18
Orbital Therapeutics
Orbital Therapeutics
Series A$270M332022Cambridge, MA, US
Board Member· Board

Leadership at Orbital Therapeutics

Giuseppe CiaramellaGiuseppe CiaramellaCo-Founder & CEO
Kristina BurowKristina BurowBoard Member

Similar to Orbital Therapeutics

Orna TherapeuticsOrna TherapeuticsCambridge, MA, USTherapeuticsest. 2019Orna TherapeuticsCambridge, MA, US · est. 2019

Orna Therapeutics, founded in 2019, is a biotech firm specializing in the design and delivery of engineered circular RNA therapeutics.

Series B · $321M130
ReviR TherapeuticsReviR TherapeuticsSan Francisco, CA, USMedicines, Therapeuticsest. 2021ReviR TherapeuticsSan Francisco, CA, US · est. 2021

ReviR Therapeutics: A genomics-based platform for developing innovative RNA-targeting medicines.

Seed · $20M27
ReNAgade TherapeuticsReNAgade TherapeuticsCambridge, MA, USRNA Therapeuticsest. 2021ReNAgade TherapeuticsCambridge, MA, US · est. 2021

ReNAgade Therapeutics: Pioneering RNA-based solutions for disease treatment through innovative medication production.

Series A · $300M123
Nextrna TherapeuticsNextrna TherapeuticsBoston, MA, USTherapeuticsest. 2020Nextrna TherapeuticsBoston, MA, US · est. 2020

NextRNA Therapeutics: Innovating RNA-directed therapeutics to combat disease-causing ncRNAs.

Series A · $56.1M33

Carol Suh's Similar Executives & Operators

Nugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to Carol Suh

Lucy LuLucy LuBoard Member · Life Science AngelsBill LittleBill LittleBoard Member · SpectrawaveMarc-Andre MarcotteMarc-Andre MarcotteBoard Member · CurvaFixEmily C. ChiuEmily C. ChiuFounder · TBDMichael HsuMichael HsuBoard Member · CurogramEmilie ChoiEmilie ChoiBoard Member · ZipRecruiter